Apogee (AACP) news
Recent news
Apogee Enterprises shares up 19.2% premarket after co raises FY profit, net sales forecasts
Apogee Enterprises Inc. (NASDAQ: APOG) shares surged 19.2% in pre-market trading following the company's announcement of an upward revision to its fiscal year (FY) profit and net sales forecasts. The company now expects FY revenue to range between $1.40 billion and $1.44 billion, up from the…
AInvest Wire · 6d agoApog sees FY adj EPS $3 to $3.40, saw $2.70 to $3.25
Apogee Enterprises (NASDAQ:APOG) has raised its full-year adjusted earnings per share (EPS) guidance to a range of $3.00 to $3.40, up from its previous estimate of $2.70 to $3.25. This update reflects improved performance in the second quarter of fiscal 2027, where the company reported adjusted EPS…
AInvest Wire · 6d agoApogee Enterprises 2Q EPS $1.07 vs. $1.10 y/y
Apogee Enterprises (NASDAQ:APOG) reported second-quarter earnings per share (EPS) of $1.07, representing a slight decline from $1.10 in the same period of the previous year . The company generated revenue of $342.7 million, a 1.1% decrease year over year, though it still outperformed analysts'…
AInvest Wire · 6d agoAbbVie highlights positive results from the phase 2 Apex part B study of Zumilokibart in moderate to severe atopic dermatitis, as a late breaker at EADV 2026
AbbVie has highlighted positive results from the phase 2 APEX part B study of Zumilokibart in patients with moderate-to-severe atopic dermatitis, as a late breaker at the European Academy of Dermatology and Venereology (EADV) 2026 conference. The study demonstrated favorable 16-week induction dose…
AInvest Wire · Sep 30, 2026AbbVie exec says Apogee fits 'very nicely' with its business development approach - Conf call
AbbVie Inc. (NYSE: ABBV) has announced plans to acquire Apogee Therapeutics (NASDAQ: APGE) in a $10.9 billion cash transaction, with the deal expected to close in the third quarter of 2026, pending regulatory and shareholder approvals . During an investor conference call on June 22, 2026, AbbVie…
AInvest Wire · Sep 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.